{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:28:39Z","timestamp":1786991319445,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K10250"],"award-info":[{"award-number":["17K10250"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jaip.2021.10.042","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T20:01:30Z","timestamp":1635451290000},"page":"558-565.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome\/Drug Reaction with Eosinophilia and Systemic Symptoms"],"prefix":"10.1016","volume":"10","author":[{"given":"Yasuhiro","family":"Mitsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Shinkuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nakamura-Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Ommori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumi","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Tohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.10.042_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019","volume":"68","author":"Shiohara","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2021.10.042_bib2","first-page":"556","article-title":"Clinical features of drug-induced hypersensitivity syndrome in 38 patients","volume":"20","author":"Um","year":"2010","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2021.10.042_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bjd.12081","article-title":"Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases","volume":"168","author":"Walsh","year":"2013","journal-title":"Br J Dermatol"},{"issue":"suppl 7","key":"10.1016\/j.jaip.2021.10.042_bib4","first-page":"S3","article-title":"Antiepileptic drug hypersensitivity syndrome","volume":"39","author":"Schlienger","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaip.2021.10.042_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2133.2006.07238.x","article-title":"Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease","volume":"155","author":"Kano","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1346-8138.2011.01365.x","article-title":"Drug eruption with eosinophilia and systemic syndrome associated with reactivation of human herpesvirus 7, not human herpesvirus 6","volume":"39","author":"Morito","year":"2012","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/j.1365-2133.2007.08167.x","article-title":"Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome","volume":"157","author":"Tohyama","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archderm.145.1.67","article-title":"Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure","volume":"145","author":"Eshki","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib9","first-page":"139","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management","volume":"16","author":"Shiohara","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2021.10.042_bib10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/1346-8138.15294","article-title":"Influence of corticosteroid therapy on viral reactivation in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"47","author":"Tohyama","year":"2020","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib11","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1128\/jvi.63.7.3161-3163.1989","article-title":"Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus","volume":"63","author":"Takahashi","year":"1989","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jaip.2021.10.042_bib12","doi-asserted-by":"crossref","first-page":"9096","DOI":"10.1073\/pnas.1305187110","article-title":"CD134 is a cellular receptor specific for human herpesvirus-6B entry","volume":"110","author":"Tang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaip.2021.10.042_bib13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12016-015-8498-3","article-title":"OX40, OX40L and autoimmunity: a comprehensive review","volume":"50","author":"Webb","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.10.042_bib14","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1182\/blood.V92.9.3338","article-title":"OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors","volume":"92","author":"Ohshima","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2021.10.042_bib15","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1172\/JCI34182","article-title":"OX40-OX40L interactions: a promising therapeutic target for allergic diseases?","volume":"117","author":"Wang","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2021.10.042_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2776(10)05003-0","article-title":"OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology","volume":"105","author":"Ishii","year":"2010","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jaip.2021.10.042_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdermsci.2016.05.001","article-title":"Preferential expression of CD134, an HHV-6 cellular receptor, on CD4T cells in drug-induced hypersensitivity syndrome (DIHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"83","author":"Miyagawa","year":"2016","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2021.10.042_bib18","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3465","article-title":"Correlation between expression of CD134, a human herpesvirus 6 cellular receptor, on CD4+ t cells and Th2-type immune responses in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"100","author":"Miyagawa","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2021.10.042_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-1759(01)00424-0","article-title":"Identification of a soluble OX40 isoform: development of a specific and quantitative immunoassay","volume":"255","author":"Taylor","year":"2001","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.jaip.2021.10.042_bib20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1189\/jlb.1210651","article-title":"Technical advance: soluble OX40 molecule mimics regulatory T cell modulatory activity on FcepsilonRI-dependent mast cell degranulation","volume":"90","author":"Sibilano","year":"2011","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jaip.2021.10.042_bib21","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3899\/jrheum.080120","article-title":"Increased serum soluble OX40 in patients with systemic sclerosis","volume":"35","author":"Komura","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s13075-014-0474-4","article-title":"Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis","volume":"16","author":"Laustsen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaip.2021.10.042_bib23","doi-asserted-by":"crossref","first-page":"adv00099","DOI":"10.2340\/00015555-3452","article-title":"The OX40 axis is associated with both systemic and local involvement in atopic dermatitis","volume":"100","author":"Elsner","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2021.10.042_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib25","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","article-title":"The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations","volume":"156","author":"Shiohara","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib27","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1128\/JCM.42.11.5189-5198.2004","article-title":"Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients","volume":"42","author":"Watzinger","year":"2004","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jaip.2021.10.042_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.08.052","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease","volume":"80","author":"Mizukawa","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaip.2021.10.042_bib30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jdermsci.2012.10.002","volume":"69","author":"Ogawa","year":"2013","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.jaip.2021.10.042_bib31","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bjd.16132","article-title":"Serum thymus and activation-regulated chemokine is associated with the severity of drug reaction with eosinophilia and systemic symptoms\/drug-induced hypersensitivity syndrome","volume":"178","author":"Nakamura-Nishimura","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/ACI.0000000000000180","article-title":"Monitoring the acute response in severe hypersensitivity reactions to drugs","volume":"15","author":"Shiohara","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.10.042_bib33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.10.042_bib34","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","article-title":"IL-5- and eosinophil-mediated inflammation: from discovery to therapy","volume":"21","author":"Kouro","year":"2009","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaip.2021.10.042_bib35","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.4049\/jimmunol.0804002","article-title":"Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome","volume":"182","author":"Takahashi","year":"2009","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2021.10.042_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcv.2018.02.011","article-title":"Human CD134 (OX40) expressed on T cells plays a key role for human herpesvirus 6B replication after allogeneic hematopoietic stem cell transplantation","volume":"102","author":"Nagamata","year":"2018","journal-title":"J\u00a0Clin Virol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821011958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821011958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:31:40Z","timestamp":1761975100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821011958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2213219821011958"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.10.042","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome\/Drug Reaction with Eosinophilia and Systemic Symptoms","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.10.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}